Anxo Pharmaceutical Co., Ltd. (TPEX:6677)

Anxo Pharmaceutical Cash Flow Statement

Financials in millions TWD. Fiscal year is January - December.

Operating Activities

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-34.13	-57.21	21.86	-12.56	19.23
Depreciation & Amortization	75.07	75.63	73.56	73.41	73.98
Other Amortization	1.14	1.08	1	0.8	0.4
Loss (Gain) From Sale of Assets	0.35	-	-0.01	-0.47	0.08
Asset Writedown & Restructuring Costs	-	-	-	-	-0.06
Stock-Based Compensation	0.8	3.85	5.31	4.74	0.75
Provision & Write-off of Bad Debts	0.79	0.15	0.16	0.27	-0.25
Other Operating Activities	-12.26	-15.4	3.54	-2.02	5.67
Change in Accounts Receivable	26.43	32.25	-11.03	-32.48	-13.38
Change in Inventory	8.6	21.45	-40.76	-4.22	28.15
Change in Accounts Payable	-15.99	1.61	-19.84	15.6	2.01
Change in Unearned Revenue	1.72	3.11	-7.79	17.83	0.79
Change in Other Net Operating Assets	2.83	45.46	-28.65	10.35	-39
Operating Cash Flow	55.34	111.97	-2.66	71.27	78.35
Operating Cash Flow Growth	-50.58%	-	-	-9.04%	30.86%

Investing Activities

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Capital Expenditures	-47.74	-42.34	-57.83	-14.59	-34.85
Sale of Property, Plant & Equipment	-	-	3.35	0.47	-
Sale (Purchase) of Intangibles	-1.66	-18.25	-0.21	-2.03	-2.83
Investment in Securities	-5.32	75.26	-125.03	-	-
Other Investing Activities	-0.5	20.59	0.48	-6.26	0.32
Investing Cash Flow	-55.22	35.26	-179.24	-22.41	-37.36

Financing Activities

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Short-Term Debt Issued	861	645	809	709.38	590.45
Long-Term Debt Issued	-	-	-	6.51	26
Total Debt Issued	861	645	809	715.89	616.45
Short-Term Debt Repaid	-798	-655	-850.38	-668	-575.08
Long-Term Debt Repaid	-67.83	-53.6	-60.11	-69.01	-76.62
Total Debt Repaid	-865.83	-708.6	-910.49	-737.01	-651.7
Net Debt Issued (Repaid)	-4.83	-63.6	-101.49	-21.12	-35.25
Issuance of Common Stock	2.74	2.64	337.5	-	-
Common Dividends Paid	-	-22.25	-	-	-
Other Financing Activities	6.43	-0.53	-	-0.6	0.68
Financing Cash Flow	4.34	-83.75	236.01	-21.72	-34.57

Net Cash Flow

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Cash Flow	4.46	63.48	54.11	27.14	6.42

Free Cash Flow

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Free Cash Flow	7.6	69.63	-60.48	56.68	43.51
Free Cash Flow Growth	-89.09%	-	-	30.27%	-0.90%
Free Cash Flow Margin	0.90%	7.78%	-6.44%	6.54%	5.28%
Free Cash Flow Per Share	0.14	1.25	-1.17	1.18	0.90
Levered Free Cash Flow	-2.79	76.1	-50.15	62.13	43.95
Unlevered Free Cash Flow	7.61	86.52	-38.85	71.62	51.93

Additional Metrics

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash Interest Paid	16.55	16.79	18.25	15.05	12.77
Cash Income Tax Paid	0.93	11.38	11.71	9.64	-0.58
Change in Working Capital	23.6	103.88	-108.07	7.09	-21.45

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jul 30, 2026

Data Sources Report a data error